What is the recommended outpatient and inpatient management, including antibiotic choices and dosing, for acute cellulitis in an otherwise healthy adult, and when should coverage for methicillin‑resistant Staphylococcus aureus be added?

Treating Cellulitis: Outpatient and Inpatient Management

First-Line Outpatient Therapy for Uncomplicated Cellulitis

Beta-lactam monotherapy is the standard of care for typical nonpurulent cellulitis, achieving 96% clinical success because the primary pathogens are beta-hemolytic streptococci and methicillin-sensitive Staphylococcus aureus. 1

Recommended Oral Regimens (5-day course)

• Cephalexin 500 mg orally every 6 hours 1, 2
• Dicloxacillin 250–500 mg orally every 6 hours 1, 2
• Amoxicillin 500 mg orally three times daily 1
• Penicillin V 250–500 mg orally four times daily 1

Treat for exactly 5 days if clinical improvement occurs (resolution of warmth/tenderness, improving erythema, afebrile); extend only if symptoms have not improved. 1 High-quality randomized controlled trial evidence demonstrates that 5-day courses are as effective as 10-day courses, with 98% clinical resolution at 14 days and no relapses by 28 days. 1 Traditional 7–14-day regimens are unnecessary and promote antimicrobial resistance. 1

---

When to Add MRSA Coverage

MRSA coverage is NOT needed for typical nonpurulent cellulitis, as MRSA is an uncommon cause even in high-prevalence settings. 1, 3 Add MRSA-active antibiotics only when specific risk factors are present:

• Penetrating trauma or injection drug use 1, 4
• Visible purulent drainage or exudate 1, 4
• Known MRSA colonization or prior MRSA infection 1, 4
• Systemic inflammatory response syndrome (SIRS): fever >38°C, heart rate >90 bpm, respiratory rate >24 breaths/min 1, 4
• Failure to respond to beta-lactam therapy after 48–72 hours 1, 4

---

MRSA-Active Oral Regimens (when indicated)

For Purulent Cellulitis (monotherapy acceptable)

• Trimethoprim-sulfamethoxazole (TMP-SMX) 1–2 double-strength tablets twice daily for 5 days 1, 4, 5
• Doxycycline 100 mg orally twice daily for 5 days 1, 4
• Clindamycin 300–450 mg orally every 6 hours for 5 days (only if local MRSA clindamycin resistance <10%) 1, 4, 5

For Nonpurulent Cellulitis Requiring MRSA Coverage (combination therapy mandatory)

Doxycycline or TMP-SMX must be combined with a beta-lactam because they lack reliable activity against beta-hemolytic streptococci. 1, 4

• TMP-SMX 1–2 double-strength tablets twice daily PLUS cephalexin 500 mg four times daily 1, 4
• Doxycycline 100 mg twice daily PLUS cephalexin 500 mg four times daily 1, 4

Clindamycin monotherapy provides coverage for both streptococci and MRSA, avoiding the need for combination therapy, but use only if local resistance is <10%. 1, 4

---

Inpatient Management and IV Therapy

Hospitalization Criteria

Admit patients with cellulitis when any of the following are present:

• Systemic inflammatory response syndrome (fever, tachycardia, hypotension, altered mental status) 1
• Signs of necrotizing infection: severe pain out of proportion, skin anesthesia, rapid progression, "wooden-hard" tissue, gas in tissue, bullous changes 1
• Severe immunocompromise or neutropenia 1
• Failure of outpatient therapy after 24–48 hours 1

First-Line IV Regimens for Uncomplicated Cellulitis (no MRSA risk factors)

• Cefazolin 1–2 g IV every 8 hours 1
• Nafcillin or oxacillin 2 g IV every 6 hours 1

First-Line IV Regimens for Complicated Cellulitis (MRSA coverage needed)

Vancomycin 15–20 mg/kg IV every 8–12 hours (target trough 15–20 mg/L) is the gold standard for hospitalized patients requiring MRSA coverage. 1, 4, 6

Alternative IV MRSA-active agents (A-I evidence):

• Linezolid 600 mg IV twice daily 1, 4
• Daptomycin 4 mg/kg IV once daily 1, 4
• Clindamycin 600 mg IV every 8 hours (only if local MRSA resistance <10%) 1, 4

Severe Cellulitis with Systemic Toxicity or Suspected Necrotizing Fasciitis

Mandatory broad-spectrum combination therapy is required for patients with signs of systemic toxicity, rapid progression, or suspected necrotizing fasciitis. 1

Recommended IV combination regimens:

• Vancomycin 15–20 mg/kg IV every 8–12 hours PLUS piperacillin-tazobactam 3.375–4.5 g IV every 6 hours 1, 4
• Vancomycin PLUS a carbapenem (meropenem 1 g IV every 8 hours) 1
• Vancomycin PLUS ceftriaxone 2 g IV daily and metronidazole 500 mg IV every 8 hours 1

Duration for severe infections is 7–14 days, individualized based on clinical response. 1

---

Adjunctive Measures

Elevation of the affected extremity above heart level for at least 30 minutes three times daily hastens improvement by promoting gravity drainage of edema and inflammatory substances. 1

Examine interdigital toe spaces for tinea pedis, fissuring, scaling, or maceration; treating these conditions eradicates colonization and reduces recurrent infection. 1

Address predisposing conditions including venous insufficiency, lymphedema, chronic edema, obesity, and eczema to reduce recurrence risk. 1, 3

Systemic corticosteroids (prednisone 40 mg daily for 7 days) could be considered in non-diabetic adults, though evidence is limited. 1

---

Critical Pitfalls to Avoid

Do NOT add MRSA coverage routinely for typical nonpurulent cellulitis without the specified risk factors; this represents overtreatment and increases antibiotic resistance. 1, 4

Do NOT use doxycycline or TMP-SMX as monotherapy for typical cellulitis; they lack reliable activity against beta-hemolytic streptococci, the predominant pathogens. 1, 4

Do NOT automatically extend therapy to 7–10 days based solely on residual erythema; extend only if warmth, tenderness, or erythema have not improved after 5 days. 1

Do NOT delay surgical consultation when any signs of necrotizing infection are present (severe pain out of proportion, skin anesthesia, rapid progression, "wooden-hard" tissue); these infections progress rapidly and require debridement. 1

Reassess patients within 24–48 hours to verify clinical response; treatment failure rates of 21% have been reported with some oral regimens. 1